Actinium Pharmaceuticals, Inc. - ATNM
About Gravity Analytica
Recent News
- 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
- 04.02.2025 - 4 - Statement of changes in beneficial ownership of securities
- 03.31.2025 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03.27.2025 - Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
- 03.27.2025 - Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives